NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Forecast, Price & News

$0.52

+0.05 (+10.62%)

(As of 09/21/2023 ET)

Compare

Today's Range: $0.47
▼
$0.55
50-Day Range: $0.45
▼
$0.99
52-Week Range: $0.38
▼
$8.77

Volume: 55,241 shs
Average Volume: 61,441 shs
Market Capitalization: $23.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Senti Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 667.8% Upside
$4.00 Price Target
Short Interest: Healthy
1.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.63) to ($1.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

625th out of 965 stocks

Biological Products, Except Diagnostic Industry

96th out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Senti Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Senti Biosciences has a forecasted upside of 667.8% from its current price of $0.52.
Amount of Analyst Coverage
Senti Biosciences has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.53% of the float of Senti Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Senti Biosciences has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Senti Biosciences has recently decreased by 6.81%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Senti Biosciences does not currently pay a dividend.
Dividend Growth
Senti Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNTI.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Senti Biosciences this week, compared to 0 articles on an average week.
MarketBeat Follows
3 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Senti Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.37% of the stock of Senti Biosciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Senti Biosciences are expected to grow in the coming year, from ($1.63) to ($1.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Senti Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Senti Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Senti Biosciences has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Senti Biosciences (NASDAQ:SNTI) Stock

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SNTI Price History

30 days | 90 days | 365 days | Advanced Chart

SNTI Stock News Headlines

September 22, 2023 | americanbankingnews.com

Critical Review: Senti Biosciences (NASDAQ:SNTI) and Voyager Therapeutics (NASDAQ:VYGR)

August 15, 2023 | msn.com

Chardan Capital Reiterates Senti Biosciences (SNTI) Buy Recommendation

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

August 11, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2023 | finance.yahoo.com

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

June 5, 2023 | finance.yahoo.com

Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

May 11, 2023 | msn.com

Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation

May 9, 2023 | finance.yahoo.com

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 2, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

April 17, 2023 | finance.yahoo.com

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

April 14, 2023 | finance.yahoo.com

Senti Bio to Participate in Upcoming Investor Conferences

March 24, 2023 | markets.businessinsider.com

Expert Ratings for Senti Biosciences

March 24, 2023 | markets.businessinsider.com

Morgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)

March 24, 2023 | benzinga.com

Senti Biosciences Stock (NASDAQ:SNTI), Dividends

March 23, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

March 22, 2023 | finance.yahoo.com

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

March 14, 2023 | finance.yahoo.com

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

February 6, 2023 | finance.yahoo.com

Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year

February 1, 2023 | finance.yahoo.com

Senti Bio to Present at the SVB Securities Global Biopharma Conference

January 30, 2023 | msn.com

Chardan Capital Maintains Buy Rating for Senti Biosciences: Here's What You Need To Know

January 27, 2023 | marketwatch.com

Senti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024

January 27, 2023 | finance.yahoo.com

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

December 27, 2022 | finance.yahoo.com

We Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth Carefully

December 19, 2022 | finance.yahoo.com

Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

See More Headlines

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Company Calendar

Last Earnings: 8/11/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNTI
CUSIP: N/A
CIK: 1854270
Web: www.sentibio.com
Phone: 650-239-2030
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +667.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,210,000.00
Net Margins: -1,785.30%
Pretax Margin: -1,785.30%
Return on Equity: -60.56%
Return on Assets: -42.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.09
Quick Ratio: 6.09

Sales & Book Value

Annual Sales: $3.05 million
Price / Sales: 7.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.90 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 44,545,000
Free Float: 38,977,000
Market Cap: $23.21 million
Optionable: Not Optionable
Beta: 2.32

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Timothy K. Lu M.D. (Age 42)
Ph.D., Co-founder, CEO, Pres & Director
Comp: $811.26k

Dr. James J. Collins Ph.D. (Age 57)
Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
Comp: $41.49k

Dr. Deborah A. Knobelman Ph.D. (Age 49)
CFO, Head of Corp. Devel. & Treasurer
Comp: $600.22k

Ms. Susan D. Berland (Age 68)
Sr. Financial Exec. & Independent Director
Comp: $54.23k

Dr. Kanya Rajangam M.D. (Age 50)
Ph.D., Head of R&D and Chief Medical Officer
Comp: $679.71k

Dr. Wilson Wong Ph.D.
Scientific Co-Founder & Member of Scientific Advisory Board

Susan Kahlert
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNTI Stock - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNTI shares.
View SNTI analyst ratings or view top-rated stocks.
What is Senti Biosciences' stock price forecast for 2023?: 4 brokerages have issued twelve-month target prices for Senti Biosciences' shares. Their SNTI share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 667.8% from the stock's current price.
View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts.
How have SNTI shares performed in 2023?: Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 63.0% and is now trading at $0.5210.
View the best growth stocks for 2023 here.
When is Senti Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SNTI earnings forecast.
How were Senti Biosciences' earnings last quarter?: Senti Biosciences, Inc. (NASDAQ:SNTI) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.06. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.29 million. Senti Biosciences had a negative net margin of 1,785.30% and a negative trailing twelve-month return on equity of 60.56%.
What ETF holds Senti Biosciences' stock ?: ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio.

What is Senti Biosciences' stock symbol?: Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI."
Who are Senti Biosciences' major shareholders?: Senti Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (4.14%) and Triatomic Management LP (0.67%).
View institutional ownership trends.
How do I buy shares of Senti Biosciences?: Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Senti Biosciences' stock price today?: One share of SNTI stock can currently be purchased for approximately $0.52.
How much money does Senti Biosciences make?: Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $23.21 million and generates $3.05 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.
How many employees does Senti Biosciences have?: The company employs 122 workers across the globe.
How can I contact Senti Biosciences?: Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio.

This page (NASDAQ:SNTI) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial